professor888
2023-03-06

Mizuho Securities analyst maintained a Buy rating on Assembly Biosciences ( – ) today and set a price target of $3.00. The company’s shares opened today at $1.53.

Syed covers the Healthcare sector, focusing on stocks such as Cytokinetics, Biogen, and Coherus Biosciences. According to , Syed has an average return of -10.9% and a 43.14% success rate on recommended stocks.

Assembly Biosciences has an analyst consensus of Moderate Buy, with a price target consensus of $2.75.

The company has a one-year high of $2.42 and a one-year low of $0.82. Currently, Assembly Biosciences has an average volume of 321.9K.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which are most likely to make moves following their insider activities.

Assembly Biosciences, Inc. is a biotechnology company, which engages in the development of products for infectious diseases, such as chronic hepatitis B virus and illnesses associated with a dysbiotic microbiome. It focuses in two innovative platform programs: oral therapeutics for the treatment of hepatitis B virus, and the oral synthetic live biotherapeutics candidate. The company was founded by Uri Lopatin on October 7, 2005 and is headquartered in Carmel, IN.

Read More on ASMB:

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

Leave a comment
24